Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Site Search
Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.
Funding will support improved detection, diagnosis, prevention, and treatment of infections related to cystic fibrosis.
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs
Nonprofit commits $20 million to fund projects and accelerate genetic therapies for CF
The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
This competition is awarding one year of free lab and office space at Bakar Labs of University of California Berkeley to applicants with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may be applied to CF.
The patient-centered outcomes research (PCOR) training manual provides discrete steps, tools, and resources that CF Center research teams can take to integrate and maintain patient/caregiver-partners in CF research.
Collaborative effort identifies 40 cases of COVID-19 across eight countries; outcomes for this high-risk population were reported in the Journal of Cystic Fibrosis